Q-omics provides the consensus-scored WDR37 profile across patient tissues and cancer cell-line models. WDR37 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, WDR37 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, WDR37 protein abundance shows 28,877 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, LIHC, and GBM as cancer lineages where WDR37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WDR37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WDR37 survival associations across molecular data types. WDR37 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WDR37 RNA expression–survival associations across cancer types. High WDR37 expression shows unfavorable associations in ACC, but favorable associations in HNSC, PAAD, MESO, LGG and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for WDR37 RNA expression.
This table summarizes WDR37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for WDR37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WDR37 shows lower tumor expression in THCA, LUAD, BRCA, KICH and COAD and higher tumor expression in LIHC. The LIHC box plot shows higher WDR37 RNA expression in tumor versus normal tissue (log2 FC = +0.810, t-test p < 0.001).
This table shows molecular features associated with WDR37 in patient tissues and cancer cell lines. In patient samples, WDR37 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, WDR37 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
